The expanded indication for pafolacianine (Cytalux) follows an initial approval in November 2021 for use in patients with ovarian cancer.
Medscape Medical News
The expanded indication for pafolacianine (Cytalux) follows an initial approval in November 2021 for use in patients with ovarian cancer.
Medscape Medical News